|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC02
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:CASNumber
|
174722-31-7
|
|
gptkbp:composition
|
gptkb:IgG1_kappa
|
|
gptkbp:contraindication
|
severe active infection
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Biogen_Idec
|
|
gptkbp:halfLife
|
18-22 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rituximab
|
|
gptkbp:indication
|
autoimmune diseases
hematological cancers
|
|
gptkbp:KEGGID
|
gptkb:D08402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:MabThera
gptkb:Rituxan
|
|
gptkbp:mechanismOfAction
|
B cell depletion
|
|
gptkbp:molecularWeight
|
143,860 Da
|
|
gptkbp:origin
|
chimeric monoclonal antibody
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201585
DB00073
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fever
infections
rash
neutropenia
infusion reaction
|
|
gptkbp:target
|
gptkb:CD20
|
|
gptkbp:UNII
|
M4O3YG8JZ2
|
|
gptkbp:usedFor
|
gptkb:pemphigus_vulgaris
gptkb:granulomatosis_with_polyangiitis
leukemia
chronic lymphocytic leukemia
rheumatoid arthritis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:granulomatosis_with_polyangiitis
|
|
gptkbp:bfsLayer
|
5
|